Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.65 |
| ▸ | MAOB | P27338 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026525 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| SCHEMBL12308294 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| SCHEMBL11955769 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| SCHEMBL12015667 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| SCHEMBL12797016 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| SCHEMBL12878038 | 1.00 | KDM1A (0.65) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| Hydrochloric Acid SCHEMBL4138814 | 0.98 | KDM1A (0.62) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| Hydrochloric Acid SCHEMBL4138819 | 0.98 | KDM1A (0.62) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| Hydrochloric Acid SCHEMBL28824531 | 0.98 | KDM1A (0.62) | KDM1AMAOBSMN1; SMN2NPSR1MAOA | |
| Hydrochloric Acid SCHEMBL6623274 | 0.98 | KDM1A (0.62) | KDM1AMAOBSMN1; SMN2NPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | claimed |
| CN-116715671-A | Application of alpha-chromene spiropiperidine compound in preparation of 5-hydroxytryptamine 2C receptor agonist | 苏州大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-113277974-B | 2-phenylcyclopropylmethylamine derivative, and preparation method and use thereof | 上海科技大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115068475-A | Application of alpha-chromene spiropiperidine compounds in preparation of 5-hydroxytryptamine 2C receptor agonists | 苏州大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-108779096-B | Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| WO-2009125853-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | 田辺三菱製薬株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | KDM1A 1290/4885MAOB 136/4885SMN1; SMN2 4703/4885 |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885SMN1; SMN2 3685/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | KDM1A 1290/4885MAOB 136/4885SMN1; SMN2 4703/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | KDM1A 3105/4885MAOB 575/4885SMN1; SMN2 2387/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885SMN1; SMN2 3685/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 141/4885SMN1; SMN2 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.